New data concerning treatment of urogenital cancer patients presented at annual congress of American Society of Clinical Oncology 2011
Journal Title: OncoReview - Year 2011, Vol 1, Issue 4
Abstract
INTRODUCTION: The annual congress of The American Society of Clinical Oncology took place between 03.06.2011 and 06.06.2011 in Chicago, the US.MATERIAL AND METHODS: Papers presented during ASCO are discussed in four sections: Testicular Cancer, Prostate Cancer, Kidney Cancer and Urothelial Carcinoma.RESULTS: About 160 original papers concerning urogenital cancers were surveyed. Phase III studies are discussed as well as the supplemental analyses of the phase III trials published during ASCO. A brief summary of phase I and phase II trials was also provided.Conclusion : The ASCO Annual Congress is the conclusion of the advances in the field of medical oncology.
Authors and Affiliations
Paweł Wiechno
Keywords
Related Articles
- EP ID EP53126
- DOI -
- Views 206
- Downloads 0
Tyrosine kinase inhibitors in hematologic malignancy: should we be concerned?
58-year-old woman with pancreatic neuroendocrine tumour
We reported a 58-year-old woman with tumor in the tail and body of pancreas measuring 70 mm in diameter who underwent distal pancreatectomy and splenectomy. Examination of a specimen of the pancreatic mass obtained histo...
Późny nawrót przewlekłej białaczki szpikowej po alogenicznym przeszczepieniu komórek macierzystych - opis przypadku
Przewlekła białaczka szpikowa obecnie w większości przypadków jest chorobą dobrze poddającą leczeniu inhibitorami kinazy tyrozynowej. Nadal jednak jedyną procedurą leczniczą dającą możliwość wyleczenia jest aloprzeszczep...
Distress and depression in cancer patients - diagnosis and treatment
Cancer diagnosis destroys previous internal and external order of patient, who has not experienced such a situation yet. The most negative emotions, which are felt in the situation of cancer diagnoses are anxiety, sadnes...
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Purpose: Somatostatin analogs are indicated for symptom control in patients with gastroenteropancreatic neuroendocrine tumors (NETs). The ability of somatostatin analogs to control the growth of well-differentiated metas...